文献速递血管炎

临床无明显肾脏受累的ANCA相关性血管炎患者的肾脏结局:多中心REVEAL队列研究

Renal outcomes in ANCA-associated vasculitis without clinically apparent kidney involvement: a multicentre REVEAL cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究基于多中心REVEAL队列,分析肾脏BVAS=0的ANCA相关性血管炎(AAV)患者肾脏预后。129例肾脏BVAS=0患者中,3年新发慢性肾脏病(CKD)累积发生率为30.7%(95%CI 21.6-42.6%);基线至1个月时间加权平均CRP(TWA-CRP)与CKD发生相关(年龄校正HR 1.21;95%CI 1.06-1.39;P<0.01)。结论提示即使尿检无异常,也应监测eGFR。

要点

  • 肾脏BVAS=0的AAV患者缓解诱导后eGFR下降,3年CKD累积发生率30.7%。
  • 基线至1个月TWA-CRP与CKD发生独立相关(年龄校正HR 1.21)。
  • 6个月时1-6个月TWA-CRP≥0.5 mg/dl提示CKD风险更高(HR 2.61)。

核心结论

  • 在临床无明显肾脏受累的AAV患者中,作为持续全身炎症替代指标的TWA-CRP与新发CKD相关。
  • 即使尿常规无异常,仍应监测eGFR。

研究设计与样本

  • 多中心REVEAL队列研究,纳入肾脏BVAS=0患者129例和肾脏BVAS≥1患者228例。
  • 按肾脏BVAS(0 vs ≥1)分析eGFR轨迹,主要结局为肾脏BVAS=0组新发CKD。

主要发现

  • 缓解诱导后,肾脏BVAS≥1组eGFR改善,而肾脏BVAS=0组eGFR下降,且该恶化趋势与治疗强度无关。
  • 3年内肾脏BVAS=0组30例发生CKD,累积发生率30.7%(95%CI 21.6-42.6%)。
  • Cox模型显示,年龄较大和基线至1个月TWA-CRP较高与新发CKD相关。
  • 基线至1个月TWA-CRP预测新发CKD的年龄校正HR为1.21(95%CI 1.06-1.39;P<0.01)。
  • 6个月界标分析中,1至6个月TWA-CRP≥0.5 mg/dl者CKD风险更高(HR 2.61;95%CI 1.01-6.78;P=0.049)。

关键数值与推荐

  • 新发CKD定义为至少两次间隔≥90天的eGFR值<60 ml/min/1.73 m2,且较基线下降≥30%。
  • 肾脏BVAS=0组3年CKD累积发生率为30.7%(95%CI 21.6-42.6%)。
  • 基线至1个月TWA-CRP每升高单位,CKD风险年龄校正HR为1.21(95%CI 1.06-1.39;P<0.01)。
  • 6个月时1至6个月TWA-CRP≥0.5 mg/dl的HR为2.61(95%CI 1.01-6.78;P=0.049)。

临床怎么用

  • 对临床无明显肾脏受累的AAV患者,即使尿检正常,也应定期监测eGFR。
  • 关注基线至1个月及1至6个月TWA-CRP水平,持续炎症可能提示CKD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Most studies on renal outcomes in ANCA-associated vasculitis (AAV) focus on GN; however, the prognosis of patients without clinically apparent kidney involvement is understudied. We aimed to characterize kidney prognosis in this overlooked subgroup. METHODS: Estimated glomerular filtration rate (eGFR) trajectories by kidney Birmingham Vasculitis Activity Score (BVAS; 0 vs ≥1) were analysed. The primary outcome was incident chronic kidney disease (CKD) in the kidney BVAS = 0 group, defined as at least two eGFR values <60 ml/min/1.73 m2 obtained at least 90 days apart, accompanied by a decline ≥30% from baseline. RESULTS: The cohort included 129 patients with kidney BVAS = 0 and 228 with kidney BVAS ≥ 1. After remission induction, eGFR improved in kidney BVAS ≥ 1 but declined in kidney BVAS = 0; this worsening trajectory in the kidney BVAS = 0 group was observed regardless of treatment intensity. Over 3 years, incident CKD occurred in 30 patients in kidney BVAS = 0 (cumulative incidence 30.7%, 95% CI 21.6-42.6%). In Cox models, older age and higher baseline-to-1-month time-weighted average CRP (TWA-CRP) were associated with incident CKD. Baseline-to-1-month TWA-CRP predicted incident CKD (age-adjusted HR 1.21; 95% CI 1.06-1.39; P < 0.01), and TWA-CRP from 1 to 6 months ≥0.5 mg/dl at the 6-month landmark identified higher risk (HR 2.61; 95% CI 1.01-6.78; P = 0.049). CONCLUSION: In AAV without clinically apparent kidney involvement, TWA-CRP, as a surrogate of sustained systemic inflammation, was associated with incident CKD. Even with unremarkable urinalysis, eGFR monitoring is warranted.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Taniguchi T, Hiwa R, Iwasaka S, et al. Renal outcomes in ANCA-associated vasculitis without clinically apparent kidney involvement: a multicentre REVEAL cohort study. Rheumatology (Oxford). 2026. PMID: 41803666. doi:10.1093/rheumatology/keag114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。